Biotechnology

Filter

Current filters:

None

Popular Filters

51 to 75 of 2475 results

Qiagen acquires unit of Enzymatics and agrees partnership with ArcherDX

Qiagen acquires unit of Enzymatics and agrees partnership with ArcherDX

12-01-2015

Netherlands-based company Qiagen has acquired the Enzyme Solutions Unit of privately-held US company…

ArcherDXBiotechnologyEnzymaticsGeneticsMergers & AcquisitionsNetherlandsQiagen

China’s FDA approves Chipscreen’s Epidaza

China’s FDA approves Chipscreen’s Epidaza

12-01-2015

Chinese biotech firm Chipscreen Biosciences has received regulatory approval of Epidaza (chidamide),…

BiotechnologychidamideChinaChipscreen BiosciencesEpidazaOncologyRegulation

Shire to spend $5.2 billion to buy NPS Pharma

Shire to spend $5.2 billion to buy NPS Pharma

12-01-2015

Recently jilted Ireland-headquartered Shire says it is to acquire NPS Pharmaceuticals, confirming recent…

BiotechnologyEuropeGattexMergers & AcquisitionsNatparaNPS PharmaceuticalsRare diseasesRevestiveShire

Sanofi and Regeneron’s alirocumab meets endpoints in cholesterol study

Sanofi and Regeneron’s alirocumab meets endpoints in cholesterol study

09-01-2015

French pharma major Sanofi and Regeneron Pharmaceuticals today announced that two new ODYSSEY trials,…

alirocumabBiotechnologyCardio-vascularRegeneron PharmaceuticalsResearchSanofi

uniQure appoints Matthew Kapusta as chief financial officer

uniQure appoints Matthew Kapusta as chief financial officer

09-01-2015

Dutch gene therapy specialist uniQure has appointed Matthew Kapusta as chief financial officer.

BiotechnologyBoardroomNetherlandsuniQureuniQure

Biogen Idec reports positive results from Phase II trial of anti-LINGO-1 in acute optic neuritis

Biogen Idec reports positive results from Phase II trial of anti-LINGO-1 in acute optic neuritis

09-01-2015

US biotech firm Biogen Idec has announced positive top-line results from its Phase II trial of anti-LINGO-1…

anti-LINGO-1Biogen IdecBiotechnologyOphthalmicsResearchUSA

Biotech industry shatters key fundraising records in 2014

08-01-2015

The biotech industry shattered records for venture investment, IPOs (initial public offerings) and M&A…

BiotechnologyFinancialGlobalLicensing

Horizon Discovery agrees to acquire Haplogen Genomics in $9 million deal

Horizon Discovery agrees to acquire Haplogen Genomics in $9 million deal

08-01-2015

Life science research tool supplier Horizon Discovery Group has agreed to acquire Haplogen Genomics,…

BiotechnologyEvent horizonHaplogen GenomicsHorizon Discovery GroupMergers & Acquisitions

BIO urges US FDA to release guidance on biosimilars

BIO urges US FDA to release guidance on biosimilars

08-01-2015

The US trade group the Biotechnology Industry Organization (BIO) has called on the Food and Drug Administration…

BiosimilarsBiotechnologyRegulationUSA

Sandoz’ Neupogen biosimilar backed by FDA advisory panel

Sandoz’ Neupogen biosimilar backed by FDA advisory panel

08-01-2015

The US Food and Drug Administration Oncologic Drugs Advisory Committee (ODAC), in a unanimous vote, recommended…

AmgenBiosimilarsBiotechnologyFilgrastimNeupogenNovartisOncologyRegulationSandozUSAZarxio

Sobi extends distribution agreement with Exelixis for Cometriq

Sobi extends distribution agreement with Exelixis for Cometriq

07-01-2015

Swedish Orphan Biovitrum today announced that its agreement with Exelixis has been restructured and extended…

BiotechnologyCometriqEuropeExelixisMarkets & MarketingOncologySobi

Isis Pharmaceuticals appoints Sarah Boye as chief business officer

Isis Pharmaceuticals appoints Sarah Boye as chief business officer

07-01-2015

Isis Pharma, the biopharma Crohn’s disease specialist, has appointed Sarah Boyce to the newly-created…

BiotechnologyBoardroomIsis PharmaIsis PharmaceuticalsUSA

Alkermes rises on positive ALKS 5461 results

07-01-2015

Shares of Ireland-headquartered biotech firm Alkermes closed up 2.6% to $60.93, having risen as much…

AlkermesALKS 5461BiotechnologyNeurologicalResearch

Cytos out-licenses VLP platform for hep B infections to OnCore Biopharma

06-01-2015

Switzerland-based Cytos Biotechnology has executed an exclusive license agreement granting privately-held…

Anti-viralsBiotechnologyCytos BiotechnologyLicensingOnCore BioPharma

23andMe and Genentech in deal to analyze genomic data for Parkinson's disease

06-01-2015

23andMe, the leading personal genetics company, and Genentech, a subsidiary of Swiss pharma giant Roche,…

23andMeBiotechnologyGenentechNeurologicalResearchRoche

Cardio3 BioSciences acquires Celdara’s OnCyte division

Cardio3 BioSciences acquires Celdara’s OnCyte division

06-01-2015

Belgian biotech firmCardio3 BioSciences has acquired OnCyte, the oncology division of privately-held…

BiotechnologyCardio3 BioSciencesCeldara MedicalMergers & AcquisitionsOncologyOnCyte

FDA staffers back approval of Novartis' biosimilar of Amgen's Neupogen

FDA staffers back approval of Novartis' biosimilar of Amgen's Neupogen

06-01-2015

In briefing papers ahead of an advisory committee meeting, agency staff at the US Food and Drug Administration…

AmgenBiosimilarsBiotechnologyImmunologicalsNeupogenNovartisRegulationUSA

Vectura links with Janssen on asthma/COPD drug development

Vectura links with Janssen on asthma/COPD drug development

06-01-2015

UK inhaled therapies developer Vectura Group has entered into a global development and licence agreement…

BiotechnologyGlobalJanssen BiotechJohnson & JohnsonLicensingResearchRespiratory and PulmonaryVectura

CytomX expands leadership team with appointment of Michael Kavanaugh as chief scientific officer

CytomX expands leadership team with appointment of Michael Kavanaugh as chief scientific officer

05-01-2015

Oncology biotech company CytomX has appointed Michael Kavanaugh as chief scientific officer and head…

BiotechnologyBoardroomCytomXOncologyUSA

Amgen and Kite Pharma collaborate on CAR T cell therapies

05-01-2015

Kite Pharma has announced a strategic research collaboration and license agreement with US biotech giant…

AmgenBiotechnologyKite PharmaLicensingOncologyResearch

Boehringer Ingelheim and BioMed X to collaborate on COPD research

Boehringer Ingelheim and BioMed X to collaborate on COPD research

05-01-2015

German family-owned drug major Boehringer Ingelheim is to collaborate with the BioMed X Innovation Center.

BiotechnologyBoehringer IngelheimGermanyResearchRespiratory and Pulmonary

51 to 75 of 2475 results

COMPANY SPOTLIGHT

Parexel

Parexel

Back to top